ABSTRACT
No abstract available.
Subject(s)
Humans , Aging , Alzheimer Disease/drug therapy , Cost of Illness , Excitatory Amino Acid Agonists/therapeutic use , Health Behavior , N-Methylaspartate/therapeutic use , Risk FactorsABSTRACT
Alzheimer's disease (AD) is the most common form of dementia caused by neurodegenerative process and is tightly related to amyloid beta (Abeta) and neurofibrillary tangles. The lack of early diagnostic biomarker and therapeutic remedy hinders the prevention of increasing population of AD patients every year. In spite of accumulated scientific information, numerous clinical trials for candidate drug targets have failed to be preceded into therapeutic development, therefore, AD-related sufferers including patients and caregivers, are desperate to seek the solution. Also, effective AD intervention is desperately needed to reduce AD-related societal threats to public health. In this review, we summarize various drug targets and strategies in recent preclinical studies and clinical trials for AD therapy: Allopathic treatment, immunotherapy, Abeta production/aggregation modulator, tau-targeting therapy and metabolic targeting. Some has already failed in their clinical trials and the others are still in various stages of investigations, both of which give us valuable information for future research in AD therapeutic development.
Subject(s)
Humans , Alzheimer Disease/immunology , Amyloid beta-Peptides/antagonists & inhibitors , Antibodies, Monoclonal/therapeutic use , Brain/metabolism , Immunotherapy , N-Methylaspartate/therapeutic use , tau Proteins/antagonists & inhibitorsABSTRACT
La población seropositiva para el VIH presenta con alta frecuencia alteraciones neurológicas clínicas. La casi totalidad de las estructuras del SNC son vulnerables al virus. El complejo de deterioro cognoscitivo/motor asociado a VIH es una entidad de alta prevalencia, bien caracterizada desde el punto de vista clínico y neuropatológico. No obstante, los exámenes de laboratorio actualmente disponibles no son específicos de esta entidad, sino sólo orientadores del diagnóstico. Como medida profiláctica se han empleado, sobre bases teóricas, los antagonistas de los receptores N-methyl-D-aspartato; se requiere aún de estudios clínicos para confirmar su eficacia. Los mejores resultados terapéuticos se han obtenido con el uso de la cidovudina (AZT), aún cuando su efecto es transitorio